Trial · NCT05321069
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 | Placebo | -183.48 | 95% Confidence Interval -210.86 to -156.10 | Milliliters (mL) | |
| Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 | Nerandomilast 9 mg BID | -138.60 | 95% Confidence Interval -165.59 to -111.61 | Milliliters (mL) | |
| Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 | Nerandomilast 18 mg BID | -114.65 | 95% Confidence Interval -141.81 to -87.50 | Milliliters (mL) | |
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial | Placebo | Acute IPF exacerbation as the first event | 38 | Participants | |
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial | Nerandomilast 9 mg BID | Acute IPF exacerbation as the first event | 32 | Participants | |
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial | Nerandomilast 18 mg BID | Acute IPF exacerbation as the first event | 38 | Participants | |
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial | Placebo | Hospitalisation for respiratory cause as the first event | 49 | Participants | |
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial | Nerandomilast 9 mg BID | Hospitalisation for respiratory cause as the first event | 45 | Participants | |
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial | Nerandomilast 18 mg BID | Hospitalisation for respiratory cause as the first event | 47 | Participants | |
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial | Placebo | Death as the first event | 16 | Participants | |
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial | Nerandomilast 9 mg BID | Death as the first event | 13 | Participants | |
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial | Nerandomilast 18 mg BID | Death as the first event | 8 | Participants | |
| Time to First Acute IPF Exacerbation or Death Over the Duration of the Trial | Placebo | Acute IPF exacerbation | 30 | Participants | |
| Time to First Acute IPF Exacerbation or Death Over the Duration of the Trial | Nerandomilast 9 mg BID | Acute IPF exacerbation | 31 | Participants | |
| Time to First Acute IPF Exacerbation or Death Over the Duration of the Trial | Nerandomilast 18 mg BID | Acute IPF exacerbation | 38 | Participants | |
| Time to First Acute IPF Exacerbation or Death Over the Duration of the Trial | Placebo | Death | 19 | Participants | |
| Time to First Acute IPF Exacerbation or Death Over the Duration of the Trial | Nerandomilast 9 mg BID | Death | 20 | Participants | |
| Time to First Acute IPF Exacerbation or Death Over the Duration of the Trial | Nerandomilast 18 mg BID | Death | 12 | Participants | |
| Time to Hospitalization for Respiratory Cause or Death Over the Duration of the Trial | Placebo | Hospitalization for respiratory cause | 59 | Participants | |
| Time to Hospitalization for Respiratory Cause or Death Over the Duration of the Trial | Nerandomilast 9 mg BID | Hospitalization for respiratory cause | 57 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05321069/results